Pharma Co. Brass Face Investor Suit Over Drug Trial Probe

By Emilie Ruscoe · December 13, 2024, 7:53 PM EST

Officers and directors of cancer treatment developer MacroGenics Inc. have been hit with a shareholder derivative action alleging they breached their fiduciary duties after the company announced three study participant deaths...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

Cottle v. Macrogenics, Inc. et al

Case Number

Court

Maryland

Nature of Suit

Securities/Commodities

Date Filed

December 11, 2024

Recent Articles By Emilie

December 16, 2024
Ginkgo Bioworks Investors Get Final OK Of $17.8M Settlement
December 06, 2024
Two Firms To Rep CVS Investors In Benefit Unit Losses Suit
November 05, 2024
Bright Health Beats Investor Suit Over COVID-19 Costs
October 30, 2024
LA Times Owner Faces Investor Suit Over Drug Co.'s Woes
October 28, 2024
Moderna Brass Hit With Investor Suit Over RSV Shot Claims
October 22, 2024
Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection
October 16, 2024
Pharma Co. Contractor Settles SEC Insider Trading Claim
September 24, 2024
Biotech RenovaCare Investors Seek OK Of $2M Deal
September 03, 2024
Teva Investors Get Go-Ahead To Resume Kickbacks Class Suit
August 02, 2024
Health Tech Co. Beats Investor Data Platform Fraud Claim